fda warning letters glp-1 compounders september 2025 Drug ad enforcement ramps up–again

FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading

22.73

★★★★☆4.8 (126)

FDA takes aim at telehealth companies for promoting unofficial weight loss drug dupes

29.54

★★★★★4.9 (98)

FDA Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling

26.44

★★★★★5.0 (157)

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not FDA-approved and can pose risks to patients. FULL STORY:🔗https://tinyurl.com/3ztf9uj2

20.37

★★★★★4.7 (84)

FDA Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded GLP-1 Marketing

25.99

★★★★★4.9 (203)

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of compounded GLP-1s, building off increasing pressure to tamp down on the sale of

27.41

★★★★★5.0 (176)

FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers

26.04

★★★★★4.8 (132)